Xuanzhubio-b
HKSE: 2575.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Yanjun Xu
- Employees
- 197
- Headquarters
- Beijing, China
- IPO year
- 2025
- Market cap
- HK$11.0B
- Website
- https://www.xuanzhubio.com
Loading 2575…
Loading profile data…Frequently asked questions about 2575
What does Xuanzhubio-b (2575.HK) do?
Xuanzhu Biopharmaceutical Co., Ltd. engages in the development, industrialization, and commercialization of small-molecule chemical drugs and macromolecular biopharmaceuticals in China. Its lead product candidates includes Core- KBP-3571 for the treatment of duodenum ulcers; XZP-3287, a CDK4/6 inhibitor for the treatment of HR+/HER2 advanced bre...
Where does 2575.HK trade?
Xuanzhubio-b (2575.HK) trades on the Hong Kong Stock Exchange.
What sector is 2575.HK in?
Xuanzhubio-b (2575.HK) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Xuanzhubio-b?
Yanjun Xu is the chief executive officer of Xuanzhubio-b (2575.HK).
Where is Xuanzhubio-b headquartered?
Xuanzhubio-b is headquartered in China.
Does 2575.HK pay a dividend?
Xuanzhubio-b (2575.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 2575.HK go public?
Xuanzhubio-b (2575.HK) completed its initial public offering in 2025.